Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPZATO KIT with Nivolumab and Relatlimab in Metastatic Melanoma with Liver Metastasis
NCT07281924Phase 2Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Nov 2026
- Primary completion
- Dec 2030
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of melphalan in melanoma, liver metastasis, sponsored by University of Wisconsin–Madison. Started Nov 2026; status: recruiting.
02
Drugs
melphalan
03
Conditions
melanomaliver metastasis
Beyond the preview
Go deeper on NCT07281924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281924.